Clinical Trial Update: Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial updating a comparison of Fluzoparib plus Bevacizumab with a dietary intervention versus Fluzoparib monotherapy as first-line maintenance in HRD± a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Fluzoparib (fluzoparib)

Snippet

Sponsor: Tongji Hospital | Conditions: Ovarian Cancer | Phase 3 | Status: RECRUITING